Over the past year, I’ve spent a fair amount of time thinking and writing about the challenges MedTech organizations face as they work to accelerate innovation while maintaining compliance. In earlier Perspectives, I explored the relationship between innovation and execution, as well as the opportunities and challenges associated with regulatory harmonization.
As I’ve continued reflecting on those topics, I find myself returning to lessons from my own experience in the MedTech industry and comparing them to what I continue to see across organizations today. That reflection has led me to a simple question: What is the business cost of operating in a compliant organization that is not fully integrated?
MedTech leaders understand the cost of noncompliance. Regulatory findings, remediation activities, and delayed submissions have visible consequences. Those risks are well understood and actively managed. What is less visible is the impact of disconnected processes, inconsistent ways of working, and inefficiencies that develop over time as organizations grow, acquire new capabilities, and adapt to changing business and regulatory environments.
Many organizations pass audits, move products through development, and achieve compliance objectives. From the outside, everything appears to be functioning as intended. Yet beneath the surface, inefficiencies can begin to accumulate. Cross-functional handoffs take longer than expected. Decisions move through multiple layers of review. Teams spend time navigating processes rather than advancing products. Different parts of the organization solve similar problems in different ways.
None of these challenges is likely to increase compliance risk or generate an audit observation, but together they can create a meaningful drag on execution. Collectively, they consume time, resources, and organizational energy that could otherwise be directed toward innovation.
This matters because today’s MedTech environment is becoming increasingly complex. Product development requires coordination across engineering, quality, regulatory, clinical, manufacturing, software, cybersecurity, and commercial teams. As products, technologies, and organizations become more interconnected, the ability to operate as an integrated system becomes increasingly important.
This is where I believe many organizations have an opportunity to rethink how they define operational effectiveness. Compliance provides the foundation for quality, patient safety, and long-term business success. But compliance alone does not create competitive advantage.
The organizations that consistently accelerate innovation are often those that focus beyond compliance. They create alignment across functions, simplify decision-making, improve handoffs, and ensure that processes, systems, governance, and teams work together toward a common objective. They recognize that innovation moves faster when the organization itself moves together.
In many ways, this is a natural continuation of the themes I discussed in my previous Perspectives. Innovation requires disciplined execution. Regulatory harmonization requires organizational alignment. And ultimately, innovation velocity depends on how effectively an organization integrates the many functions, processes, and decisions required to bring products to market.
As MedTech leaders look ahead, there will be no shortage of external challenges competing for attention. Regulatory change, emerging technologies, competitive pressures, and evolving customer expectations will continue to shape the industry. But there is also value in looking inward.
The next opportunity to accelerate innovation may not come from a new technology, a new market, or a new acquisition. It may come from identifying and removing the inefficiencies that quietly slow progress every day.
October 21, 2026